IRCT20120520009801N11尚未招募3 期
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and Ecocardiography parameters in patients with congenital heart diseases with left-to-right shunt: a triple-blind, randomized, placebo-controlled trial
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1 month 至 18 years（—）
- 性别
- All
入选标准
- •Patients with congenital heart diseases with left-to-right shunt
- •Heart failure
- •One month to 18 years
排除标准
- •Patients with various types of cardiomyopathy
- •Patients with myocarditis
- •Patients with pericarditis and cardiac tamponade
- •Patients with thiamine deficiency (beriberi) based on clinical symptoms
- •Patients with severe anemia
- •Patients with thyrotoxicosis
- •Presence of pulmonary infection
- •?Chronic kidney disease in GFR < 20 ml/min/173 m2
- •?Patients on dialysis
研究者
相似试验
已完成
3 期
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
尚未招募
3 期
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology
已完成
1 期
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
招募中
3 期
Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function testsIRCT20191209045671N3Semnan University of Medical Sciences60